T

Telomir Pharmaceuticals Inc
NASDAQ:TELO

Watchlist Manager
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Watchlist
Price: 4.27 USD -0.7%
Market Cap: 126.4m USD
Have any thoughts about
Telomir Pharmaceuticals Inc?
Write Note

Telomir Pharmaceuticals Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Telomir Pharmaceuticals Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
T
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Other Non-Cash Items
$9.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Non-Cash Items
$3.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Other Non-Cash Items
$14.3B
CAGR 3-Years
6%
CAGR 5-Years
90%
CAGR 10-Years
80%
Pfizer Inc
NYSE:PFE
Other Non-Cash Items
$6.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
35%
Merck & Co Inc
NYSE:MRK
Other Non-Cash Items
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
27%
Eli Lilly and Co
NYSE:LLY
Other Non-Cash Items
$4.5B
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
26%
No Stocks Found

Telomir Pharmaceuticals Inc
Glance View

Market Cap
126.4m USD
Industry
Pharmaceuticals

Telomir Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2024-02-09. Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The firm is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.

TELO Intrinsic Value
1.47 USD
Overvaluation 66%
Intrinsic Value
Price
T

See Also

What is Telomir Pharmaceuticals Inc's Other Non-Cash Items?
Other Non-Cash Items
9.1m USD

Based on the financial report for Dec 31, 2023, Telomir Pharmaceuticals Inc's Other Non-Cash Items amounts to 9.1m USD.

Back to Top